

# *Long QT syndrome*



P Maury  
University Hospital Rangueil  
Toulouse, France

# History

## Jervell A & Lange-Nielsen F

—  
*" Congenital deaf-mutism, functional heart-disease  
with prolongation of the QT interval and sudden death "*  
*Am Heart 1957*

## Romano C

*" Aritmie cardiache rare dell'eta pediatrica »*  
*Clin Pediatr 1963*

## Ward OC

*" A new familial cardiac syndrome in children «*  
*J Irish Med Assoc 1964*

# What about the definition ?

**TABLE 1. 1985 LQTS Diagnostic Criteria**

Major	Minor
Prolonged QT interval ( $QT_c > 440$ msec)	Congenital deafness
Stress-induced syncope	Episodes of T-wave alternans
Family members with LQTS	Low heart rate (in children)
	Abnormal ventricular repolarization

*(Schwartz, Am Heart J 1985)*


*(Schwartz, Circulation 1993)*

Good specificity  
by poor sensitivity

**TABLE 2. 1993 LQTS Diagnostic Criteria**

	Points
<b>ECG findings*</b>	
A. $QT_c$ †	
$\geq 480$ msec <sup>1/2</sup>	3
460-470 msec <sup>1/2</sup>	2
450 msec <sup>1/2</sup> (in males)	1
B. Torsade de pointes‡	2
C. T-Wave alternans	1
D. Notched T wave in three leads	1
E. Low heart rate for age§	0.5
<b>Clinical history</b>	
A. Syncope‡	
With stress	2
Without stress	1
B. Congenital deafness	0.5
<b>Family history  </b>	
A. Family members with definite LQTS#	1
B. Unexplained sudden cardiac death below age 30 among immediate family members	0.5

# What about the definition ?



25% of genotyped LQT have ... normal QTc (same for LQT1, 2 or 3)

# What about the definition ?

currently

## HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

1. LQTS is diagnosed:
  - a. In the presence of an LQTS risk score  $\geq 3.5$  in the absence of a secondary cause for QT prolongation *and/or*
  - b. In the presence of an unequivocally pathogenic mutation in one of the LQTS genes *or*
  - c. In the presence of a QT interval corrected for heart rate using Bazett's formula (QTc)  $\geq 500$  ms in repeated 12-lead electrocardiogram (ECG) and in the absence of a secondary cause for QT prolongation.
2. LQTS can be diagnosed in the presence of a QTc between 480–499 ms in repeated 12-lead ECGs in a patient with unexplained syncope in the absence of a secondary cause for QT prolongation and in the absence of a pathogenic mutation.

# What about the definition ?

currently

## HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

1. LQTS is diagnosed:
  - a. In the presence of an LQT mutation and/or absence of a secondary cause
  - b. In the presence of an unexplained syncope and a mutation in one of the LQT genes
  - c. In the presence of a QT interval  $\geq 480$  ms using Bazett's formula ( $QTc$ ) on a 12-lead electrocardiogram (ECG) in the absence of a secondary cause for QT prolongation

2. LQTS can be diagnosed in the presence of a QTc interval  $\geq 480$ – $499$  ms in repeated 12-lead ECGs, unexplained syncope in the absence of a secondary cause for QT prolongation and in the presence of a mutation.

TABLE 2. 1993 LQTS Diagnostic Criteria

	Points
ECG findings*	
A. $QTc$ †	
$\geq 480$ msec <sup>1/2</sup>	3
460-470 msec <sup>1/2</sup>	2
450 msec <sup>1/2</sup> (in males)	1
B. Torsade de pointes‡	2
C. T-Wave alternans	1
D. Notched T wave in three leads	1
E. Low heart rate for age§	0.5
Clinical history	
A. Syncope‡	
With stress	2
Without stress	1
B. Congenital deafness	0.5
Family history	
A. Family members with definite LQTS#	1
B. Unexplained sudden cardiac death below age 30 among immediate family members	0.5

# Some help ?


## Treadmill

4 min recovery: QTc > 445 ms

*Swan H, JACC 1999*

*Sy RW, Circulation 2011*

*Horner RM, Heart Rhythm 2011*



## Valsalva, cold pressor test

*Mitsutake A, Circulation 1981*



## Standing ECG

*Viskin S, et al. 2010*

## Epinephrin test

*Ackerman, Mayo Clin Proc 2002*

*Shimizu, Heart Rhythm 2004*



# How to measure QT ?

## 1. Measurement

II, V2 or V5-V6 (or lead with longest QT) 50 mm/sec

« Surawicz technique »

Stable sinus rhythm between 50 and 80 bpm

Otherwise averaged 3-5 beats

## 2. Correction

Bazett formula

$$QTc = QT \text{ (ms)} / \sqrt{RR \text{ (sec)}}$$



# Long QT is not an always easy diagnosis !

on 902 physicians asked to measure QT interval ...

	LQTS	LQTS	Control	Control
Correct results (%)	QT	QTc	QT	QTc
Arrhythmia specialists	73%	73%	91%	72%
Cardiologists	75%	53%	67%	48%
Non-cardiologists	68%	32%	61%	31%


## Correct diagnosis of real long QT

- > 80 % électrophysiologistes
- < 50 % cardiologistes
- < 40 % non cardiologistes

## Correct diagnosis of any QT (normal or abnormal)

- 62 % électrophysiologistes
- < 25 % cardiologistes and non cardiologistes

# And in newborns ?



repeated ECG + bradycardia + family ECG/history + Holter + genetic

*Guidelines for the interpretation of the neonatal electrocardiogram.  
Eur Heart J. 2002 Sep;23(17):1329-44.*

# Epidemiology


prevalence  $> 1/2000$  living births  
(based on QTc  $> 460$  ms and positive genotype)  
*(Schwartz P, Circulation 2009)*

First event childhood, teen, young adults ( $< 40$  yo)

Mean age SD 21 years old but persisting risk with age + + +

One of the causes of SIDS (10-15%) (LQT1, LQT3)



**LQT = 20 % SD between 1 and 13 yo**  
**LQT = 30 % SD between 13 and 20 yo**




**TABLE 4. Sensitivity and Specificity of Genotype Identification by Other Cardiologists**

Genotype Identification	LQT1	LQT2	LQT3
Individual ECG evaluation (n=146), %			
Sensitivity	61 (54–69)	62 (55–71)	33 (27–39)
Specificity	71 (63–78)	87 (85–90)	98 (96–100)
Family-grouped ECG evaluation (n=29), %			
Sensitivity	77 (64–82)	79 (58–92)	54 (33–83)
Specificity	81 (78–83)	88 (71–100)	100 (100)

# ECG



*(Shimizu, PACE 1996)*




T wave alternans highly predictive of torsades-de-pointes  
*(Zareba, JACC 1994)*

# Other arrhythmias

## Sinus node bradycardia / sick sinus syndrome (pauses)

1/3 patients (LQT 3 and LQT 4)

## Atrial arrhythmias (Afib, atrial salvos)



**AV block and « pseudo » AV block (neonates) (LQT 2 and LQT 3)**

# Genetical heterogeneity

GENE	LOCUS	PROTEIN
<b>Long QT Syndrome</b>		
<i>Major LQTS Genes</i>		
<i>KCNQ1 (LQT1)</i>	11p15.5	I <sub>Ks</sub> potassium channel α subunit (K <sub>v</sub> LQT1, K <sub>v</sub> 7.1)
<i>KCNH2 (LQT2)</i>	7q35-36	I <sub>Kr</sub> potassium channel α subunit (HERG, K <sub>v</sub> 11.1)
<i>SCN5A (LQT3)</i>	3p21-p24	Cardiac sodium channel α subunit (Na <sub>v</sub> 1.5)
<i>Minor LQTS Genes</i> (listed alphabetically)		
<i>AKAP9</i>	7q21-q22	AKAP9
<i>CACNA1C</i>	12p13.3	Voltage gated L-type calcium channel (Ca <sub>v</sub> 1.2)
<i>CALM1</i>	14q32.11	Calmodulin
<i>CALM2</i>	2p21	Calmodulin
<i>CAV3</i>	3p21	Caveolin-3
<i>KCNE1</i>	19q13.32	K <sub>v</sub> 7.1 potassium channel beta subunit (Mink)
<i>KCNE2</i>	19q13.32	K <sub>v</sub> 11.1 potassium channel beta subunit (MiRP1)
<i>KCNJ5</i>	17q24.3	Potassium inwardly-rectifying channel (Kir3.4)
<i>SCN4B</i>	11q23.3	Sodium channel beta 4 subunit
<i>SNTA1</i>	20q11.2	Syntrophin-alpha 1
<b>Ankyrin-B Syndrome</b>		
<i>ANK2</i>	4q25-q27	Ankyrin B
<b>Andersen-Tawil Syndrome</b>		
<i>KCNJ2 (ATS1)</i>	17q23	I <sub>K1</sub> potassium channel (Kir2.1)
<b>Timothy Syndrome</b>		
<i>CACNA1C</i>	12p13.3	Voltage gated L-type calcium channel (Ca <sub>v</sub> 1.2)

> 90%


20% without (known) mutation

# LQT 1

(Keating et al., Science 1991)

**Mutation KCNQ1 (11p15.5)**

**$\alpha$  subunit  $IK_s$**



**50 % genotyped families or cases (Khan et al., Am Heart J 2002, Splawsky, Priori)**

**Ample assymetrical T wave (large base)**

**Arrhythmias: at exercice (swimming) or emotion/stress > 95 %**




# LQT 2

(Curran ME et al., Cell 1995)

**Mutation KCNQ2 (HeRG)**

**(7q35-36)**

**$\alpha$  subunit IK<sub>R</sub>**



**30/45 % genotyped families or cases (Khan et al., Am Heart J 2002, Splawsky, Priori)**

**Noched/flat T wave**


**Arrhythmias: exercise 15 %, stress (sounds) 35 %**

**rest (stress ? noise ? dream ? arousal ?) 50 %**


# LQT 3

(Wang Q et al., Cell 1995)

**Mutation SCN5A (3p21-24)  $\alpha$  subunit  $I\text{N}_A$**



Ample T wave and  
long ST segment



**5/15 % genotyped families or cases (Khan et al., Am Heart J 2002, Splawsky, Priori)**

Arrhythmias: 3/4 at rest (pause dependant)

# Andersen-Tawill syndrome (LQT 7)

(Plaster NM et al., Cell 2001)

## K sensitive-periodic paralysis

### Malformations

### Arrhythmias:

PVC, bidirectional VT


Torsades de pointes

SD more exceptional

especially when hypoK

**Mutation on KCNJ2 (17q23) (IK1)**

**« Normal » QT and U waves**




# Prognosis and risk stratification

## Mortality in symptomatic untreated patients

5 % yearly

(Schwartz Am H J 1975, Eur H J 1985)


## Ten times lower when treated




ORIGINAL ARTICLE

## Risk Stratification in the Long-QT Syndrome

Silvia G. Priori, M.D., Ph.D., Peter J. Schwartz, M.D.,  
Carlo Napolitano, M.D., Ph.D., Raffaella Bloise, M.D., Elena Ronchetti, Ph.D.,  
Massimiliano Grillo, M.D., Alessandro Vicentini, M.D., Carla Spazzolini, M.V.,  
Janni Nastoli, B.S., Georgia Bottelli, B.S., Roberta Folli, B.S.,  
and Donata Cappelletti, B.S.



# risk SD/syncope before 40 yo



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

## Risk Stratification in the Long-QT Syndrome

Silvia G. Priori, M.D., Ph.D., Peter J. Schwartz, M.D.,  
Carlo Napolitano, M.D., Ph.D., Raffaella Bloise, M.D., Elena Ronchetti, Ph.D.,  
Massimiliano Grillo, M.D., Alessandro Vicentini, M.D., Carla Spazzolini, M.V.,  
Janni Nastoli, B.S., Georgia Bottelli, B.S., Roberta Folli, B.S.,  
and Donata Cappelletti, B.S.

# Prognosis and risk stratification

## Populations at high risk

- Jervell-Lange Nielsen
- Timothy syndrome
- QTc > 500 ms
- first event during childhood
- specific mutations
  - missense mutations cytoplasmic loop (LQT1)
  - dominant-negative ion current effects (LQT2)
  - missense mutations pore loop (men LQT2)
  - specific mutations ((KCNQ1-A341V)
  - > 1 mutation

## Populations at low risk

- specific mutations
  - missense mutations C terminal (LQT1)
- asymptomatic LQT1 males

# Management of long QT patients

## Life style modifications

- avoid any QT lengthening-drug
- avoid any K, Mg or Ca depletion
- avoid competitive sport and intense physical activity
- avoid swimming without supervision (LQT1)
- avoid sudden loud noises (LQT2)

### Competition possible ?

- asymptomatic and no familial sudden deaths
- borderline QTc
- under BB therapy
- automated external defibrillator available
- no LQT1



# Management of long QT patients

## Medical therapy

### Beta-blockers

decrease symptoms (0,31 vs 0,97 events/year)

decrease mortality (6 % at 3 years, 9 % at 15 years)

*No randomized trial*

Full dosing when possible


avoid metoprolol

propranolol 2-3 mg/kg (child)

nadolol 2-3 mg/kg (child)

# BB even for normal QT in genotyped + pts

Goldenberg I, JACC 2011;57:51-59



# Still a place for pace-maker ?

*(DDD without algorithms allowing pauses)*

- . severe symptomatic bradycardia under BB ?*
  - . Bradycardia-induced arrhythmias ?*
  - . sick sinus syndrome ? (LQT 3, LQT 4)*

*Currently only with ICD*

*Newborn or young children with 2/1 AV block ?*

# *Left cardiac sympathetic denervation*

*(lower half left stellate gg + left T2-T4)*

*Surgically (left supraclavicular) or minimally invasive (videoscropy)*

*Experienced centers*

## **not a perfect therapy**


7% SD and 50% symptoms

Schwartz P, et al. Circulation. 2004;109:1826-33

- CI to BB
- high risk children/infants instead of ICD
- syncope despite BB ?
- Electrical storm despite BB

# However ...

Priori S, et al. JAMA 2004




24 % SD in high risk patients (SD, syncope despite BB)

(Dorostkar, *Circulation* 1999)

32 % SD/syncope at 5 years in symptomatic pts treated by BB

(Moss, *Circulation* 2000)

# However ...



LQT with syncope

*No control study*

*High risk patients (SD or recurring syncope under BB)*

*1.3 % mortality at 3 years vs 14 % at 8 years without ICD*  
*(Zareba, JCE 2003)*

keep the BB !!!!

## Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them? Circulation. 2010

### Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry


Peter J. Schwartz, MD; Carla Spazzolini, DVM, MS; Silvia G. Priori, MD, PhD; Lia Crotti, MD, PhD; Alessandro Vicentini, MD; Maurizio Landolina, MD; Maurizio Gasparini, MD; Arthur A.M. Wilde, MD; Reinoud E. Knops, MD; Isabelle Denjoy, MD; Lauri Toivonen, MD; Gerold Mönning, MD; Majid Al-Fayyadh, MD; Luc Jordaens, MD; Martin Borggrefe, MD; Christina Holmgren, MD; Pedro Brugada, MD, FAHA; Luc De Roy, MD; Stefan H. Hohnloser, MD; Paul A. Brink, MD

233 implanted LQT patients (30 +/- 17 yo) FU 4.5 ans

- 11 % inappropriate th
- 25% complications
- 3 % death (non-arrhythmic)
- 28% appropriate shock

### Score risk

- cardiac arrest
- symptoms despite BB
- QTc > 500 ms
- implantation < 20 yo





**Executive summary: HRS/EHRA/APHS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes**

Silvia G. Priori, (HRS Chairperson)<sup>1</sup>, Arthur A. Wilde, (EHRA Chairperson)<sup>2</sup>, Minoru Horie, (APHS Chairperson)<sup>3</sup>, Yongkeun Cho, (APHS Chairperson)<sup>4</sup>, Elijah R. Behr<sup>5</sup>, Charles Berul<sup>6</sup>, Nico Blom<sup>7\*</sup>, Josep Brugada<sup>8</sup>, Chern-En Chiang<sup>9</sup>, Heikki Huikuri<sup>10</sup>, Prince Kannankeril<sup>11‡</sup>, Andrew Krahn<sup>12</sup>, Antoine Leenhardt<sup>13</sup>, Arthur Moss<sup>14</sup>, Peter J. Schwartz<sup>15</sup>, Wataru Shimizu<sup>16</sup>, Gordon Tomaselli<sup>17†</sup>, Cynthia Tracy<sup>18</sup>

